AKT2
This gene is a putative oncogene encoding a protein belonging to a subfamily of serine/threonine kinases containing SH2-like (Src homology 2-like) domains, which is involved in signaling pathways. The gene serves as an oncogene in the tumorigenesis of cancer cells For example, its overexpression contributes to the malignant phenotype of a subset of human ductal pancreatic cancers. The encoded protein is a general protein kinase capable of phophorylating several known proteins, and has also been implicated in insulin signaling.
| Full Name | AKT serine/threonine kinase 2 |
| Gene ID | Human: 208 Mouse: 11652 Rat: 25233 Monkey: 700591 |
| UniProt ID | Human: P31751 Mouse: Q60823 Rat: P47197 |
| Alternative Names | PKBB; PRKBB; HIHGHH; PKBBETA; RAC-BETA;RAC-beta serine/threonine-protein kinase;PKB beta;RAC-PK-beta;murine thymoma viral (v-akt) homolog-2;protein kinase Akt-2;protein kinase B beta;putative v-akt murine thymoma viral ;oncoprotein 2;rac protein kinase beta;v-akt murine thymoma viral oncogene homolog 2 |
Product List
Loading...
Magic™ Human AKT2 (E17K) BaF3 Cell Line
[CAT#: S01YF-0324-KX144]
- Product Category:
- Membrane Protein Stable Cell Lines
- Target Protein: AKT2 (E17K) Target Family: Kinases/Enzyme Target Protein Species: Human Host Cell Type: BaF3 Assay Types: Functional assay and biological assay
mProX™ Human AKT2 Stable Cell Line
[CAT#: S01YF-1123-KX146]
- Product Category:
- Membrane Protein Stable Cell Lines
- Target Protein: AKT2 Target Family: Kinases/Enzyme Drug Discovery Assays and Products Target Protein Species: Human Host Cell Type: CHO-K1; HEK293
Can't find the products you're looking for? Optimize our parameters for better results.
Filter By Tag
Note: All of our products are for Research Use Only (RUO). NOT intended for diagnostic, therapeutic or clinical use. We DO NOT offer patients any direct products or services. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
